- Arcos Dorados Holdings Inc (NYSE:ARCO) reported third-quarter FY22 sales growth of 27% year-on-year to $921.7 million, beating the consensus of $902.19 million.
- Excluding Venezuela, Consolidated revenue totaled $916.3 million, rising 26.7% in U.S. dollars and 38.9% in constant currency.
- Systemwide comparable sales grew 34.2% Y/Y, Excluding Venezuela, driven primarily by higher guest traffic and market share gains across the region.
- The operating margin was 8%, and the operating income for the quarter was $73.9 million.
- Adjusted EBITDA for the quarter was $102.65 million with an adjusted EBITDA margin of 11.2%, down 120 basis points versus last year.
- EPS of $0.22 beat the analyst consensus of $0.11.
- The company held $319.1 million in cash and equivalents as of September 30, 2022.
- Price Action: ARCO shares are trading higher by 7.67% at $7.86 on the last check Wednesday.
Celularity And Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement To Distribute Biovance And Biovance 3l Ocular For Ophthalmic Applications; Terms Of The Agreement Are Not Disclosed.
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC ("Verséa
